Literature DB >> 11550282

Nonrandom distribution of interspersed repeat elements in the BCR and ABL1 genes and its relation to breakpoint cluster regions.

A R Jeffs1, E Wells, C M Morris.   

Abstract

The Philadelphia translocation, t(9;22)(q34;q11), is the microscopically visible product of recombination between two genes, ABL1 on chromosome 9 and BCR on chromosome 22, and gives rise to a functional hybrid BCR-ABL1 gene with demonstrated leukemogenic properties. Breakpoints in BCR occur mostly within one of two regions: a 5 kb major breakpoint cluster region (M-Bcr) and a larger 35 kb minor breakpoint cluster region (m-Bcr) towards the 3' end of the first BCR intron. By contrast, breakpoints in ABL1 are reported to occur more widely across a >200 kb region which spans the large first and second introns. The mechanisms that determine preferential breakage sites in BCR, and which cause recombination between BCR and ABL1, are presently unknown. In some cases, Alu repeats have been identified at or near sequenced breakpoint sites in both genes, providing indications, albeit controversial, that they may be relevant. For the present study, we carried out a detailed analysis of genomic BCR and ABL1 sequences to identify, classify, and locate interspersed repeat sequences and to relate their distribution to precisely mapped BCR-ABL1 recombination sites. Our findings confirm that Alu are the most abundant class of repeat in both genes, but that they occupy fewer sites than previously estimated and that they are distributed nonrandomly. r-Scan statistics were applied to provide a measure of repeat distribution and to evaluate extremes in repeat spacing. A significant lack of Alu elements was observed across the major and minor breakpoint cluster regions of BCR and across a 25-kb region showing a high frequency of breakage in ABL1. These findings counter the suggestion that occurrence of Alu at BCR-ABL1 recombination sites is likely by chance because of the high density of Alu in these two genes. Instead, as yet unidentified DNA conformation or nucleotide characteristics peculiar to the preferentially recombining regions, including those Alu elements present within them, more likely influence their fragility. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11550282     DOI: 10.1002/gcc.1176

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  6 in total

Review 1.  Mechanisms leading to nonrandom, nonhomologous chromosomal translocations in leukemia.

Authors:  Susanne M Gollin
Journal:  Semin Cancer Biol       Date:  2006-10-26       Impact factor: 15.707

2.  PREVENTING THE CHROMOSOMAL TRANSLOCATIONS THAT CAUSE CANCER.

Authors:  Robert Hromas; Elizabeth Williamson; Suk-Hee Lee; Jac Nickoloff
Journal:  Trans Am Clin Climatol Assoc       Date:  2016

3.  Common chromatin structures at breakpoint cluster regions may lead to chromosomal translocations found in chronic and acute leukemias.

Authors:  Reiner Strick; Yanming Zhang; Neelmini Emmanuel; Pamela L Strissel
Journal:  Hum Genet       Date:  2006-03-30       Impact factor: 4.132

4.  Non random distribution of genomic features in breakpoint regions involved in chronic myeloid leukemia cases with variant t(9;22) or additional chromosomal rearrangements.

Authors:  Francesco Albano; Luisa Anelli; Antonella Zagaria; Nicoletta Coccaro; Paola Casieri; Antonella Russo Rossi; Laura Vicari; Vincenzo Liso; Mariano Rocchi; Giorgina Specchia
Journal:  Mol Cancer       Date:  2010-05-25       Impact factor: 27.401

Review 5.  How does DNA break during chromosomal translocations?

Authors:  Mridula Nambiar; Sathees C Raghavan
Journal:  Nucleic Acids Res       Date:  2011-04-15       Impact factor: 16.971

6.  VNTR polymorphism in the breakpoint region of ABL1 and susceptibility to bladder cancer.

Authors:  Min-Hye Kim; Gi-Eun Yang; Mi-So Jeong; Jeong-Yeon Mun; Sang-Yeop Lee; Jong-Kil Nam; Yung Hyun Choi; Tae Nam Kim; Sun-Hee Leem
Journal:  BMC Med Genomics       Date:  2021-05-05       Impact factor: 3.063

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.